MetaCap

NRX Pharmaceuticals (NRXP) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed NRX Pharmaceuticals (NRXP) over the past year, gaining 3.0% versus a gain of 0.9%. Over five years, PDSB leads with a -92.5% price change compared with -96.8% for NRXP. PDS Biotechnology is the larger company by market cap ($95.4 million vs $95.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NRXP+0.94%PDSB+2.97%
+126%+22%-83%
Nov 21, 20251 yearNov 20, 2026
NRXP-95.81%PDSB-92.26%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NRXP versus PDSB key metrics
MetricNRXPPDSB
Share price$2.15$0.7774
Market cap$95.31M$95.39M
1-day change-15.69%-3.70%
YTD return-20.66%+0.96%
1-year return+0.94%+2.97%
5-year return-96.81%-92.46%
EPS (TTM)$-0.33$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.23M—
Net income (latest FY)$-28.62M$-34.50M
Gross margin58.78%—
Operating margin-1324.41%—
Net margin-2336.49%—
52-week high$5.06$1.79
52-week low$1.62$0.195
Distance from 52-week high-57.47%-56.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1702.33%+478.85%
Average volume1.07M25.64M
Shares outstanding44.33M122.70M
Employees2921
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NRX Pharmaceuticals

NRXP stock →

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

NRXP vs PDSB FAQ

Which is bigger, NRX Pharmaceuticals or PDS Biotechnology?

PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $95.31M for NRX Pharmaceuticals (NRXP).

Which stock has performed better over the past year, NRXP or PDSB?

PDSB returned +2.97% over the past 12 months, compared with +0.94% for NRXP (price return, excluding dividends). Past performance does not predict future results.

Are NRX Pharmaceuticals and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons